ELVN · Enliven Therapeutics, Inc.

$57.86 -2.64 (-4.36%) At close · Aug 28

Market Cap

$4.43B

73.27M

The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.

Type	Filing Date	Period
10-Q	2026-08-05	2026-06-30
8-K	2026-08-05	—
8-K	2026-06-12	2026-06-11
8-K	2026-06-11	—
8-K	2026-06-10	2026-06-09
Investor Event Transcript	2026-06-04	2026-06-30
8-K	2026-05-07	—
10-Q	2026-05-07	2026-03-31
DEF 14A	2026-04-27	2026-06-09
10-K	2026-03-03	2025-12-31
8-K	2026-03-03	—
8-K	2026-01-07	2026-01-06
8-K	2025-12-11	2025-12-09
8-K/A	2025-11-13	2025-11-12
8-K	2025-11-12	—
10-Q	2025-11-12	2025-09-30
10-Q	2025-08-13	2025-06-30
8-K	2025-08-13	—
8-K	2025-06-25	2025-06-24
8-K	2025-06-16	2025-06-13
8-K	2025-06-13	—
10-Q	2025-05-14	2025-03-31
8-K	2025-05-14	—
DEF 14A	2025-04-28	2025-06-24
8-K	2025-03-13	—
10-K	2025-03-13	2024-12-31
8-K	2024-11-13	—
10-Q	2024-11-13	2024-09-30
8-K	2024-08-13	—
10-Q	2024-08-13	2024-06-30
8-K	2024-06-18	—
8-K/A	2024-05-29	2024-04-08
8-K	2024-05-14	—
10-Q	2024-05-14	2024-03-31
DEF 14A	2024-04-26	2024-06-18
8-K	2024-04-11	—
8-K	2024-04-09	2024-04-08
8-K	2024-03-19	—
8-K	2024-03-14	—
10-K	2024-03-14	2023-12-31
8-K	2023-11-09	—
10-Q	2023-11-09	2023-09-30
8-K	2023-08-10	—
10-Q	2023-08-10	2023-06-30
8-K	2023-06-26	2023-06-23
8-K	2023-06-23	—
8-K	2023-05-11	—
10-Q	2023-05-11	2023-03-31
DEF 14A	2023-04-28	2023-06-23
8-K/A	2023-03-21	2023-02-23

Showing 1–50 of 92 filings

Key facts CIK 1672619 CUSIP 29337E102 13F (30d) 198 filings 195 filers Visit website Investor relations